US-based TOLMAR Pharmaceuticals has announced that it now holds exclusive distribution rights to ELIGARD, a gonadotropin releasing hormone (GnRH) agonist, in the US and Puerto Rico as a prescription medication for the palliative treatment of advanced prostate cancer.
ELIGARD (leuprolide acetate for injectable suspension) is designed to reduce the amount of testosterone in the body by reducing its production.
The company said that it is not a cure for advanced prostate cancer and testosterone is known to stimulate the growth of prostate cancer cells.
Following marketing approval from the US Food and Drug Administration (FDA), ELIGARD was launched in the US in 2002.
In the US, prostate cancer is the second leading cause of cancer death in men after lung cancer.
According to the National Cancer Institute, 233,000 new US cases will be diagnosed and 29,480 men will die of the disease in 2014.
TOLMAR Pharmaceuticals CEO Susan Rodriguez said the company is happy to regain the sales and marketing rights for ELIGARD in the US and Puerto Rico, and carry forward the significant history and experience in the urology market long-established by TOLMAR Inc., the company that developed ELIGARD.
"TOLMAR Pharmaceuticals has launched a commercial organization to advance ELIGARD into the future, and is dedicated to supporting healthcare providers and their patients with advanced prostate cancer," Rodriguez said.
Currently, TOLMAR Pharmaceuticals is working to make sure that both physicians and patients have a continuity of product supply and unmatched support and patient care services.
TOLMAR Inc., original developer of ELIGARD, will continue to manufacture the drug for worldwide distribution.